title: Increasing therapeutic efficacy in MPN.
abstract: In this issue of Blood, Bhagwat et al describe an elegant series of experiments showing that genetic deletion in the hematopoietic system of Janus kinase 2 (JAK2) abrogates initiation of myeloproliferative disease and substantial disease regression if deleted once disease is initiated.
authors.affiliation: GUY'S AND ST THOMAS' NHS FOUNDATION TRUST.
authors.forename: Claire N
authors.initials: CN
authors.lastname: Harrison
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods*; D053614:Janus Kinase 2 / Q000235:genetics*; D058990:Molecular Targeted Therapy / Q000379:methods*; D009196:Myeloproliferative Disorders / Q000188:drug therapy*
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2